We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you’d have done very well indeed. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?
Given this risk, we thought we’d take a look at whether PRISM BioLabLTD (TSE:206A) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we’ll determine its cash runway by comparing its cash burn with its cash reserves.
When Might PRISM BioLabLTD Run Out Of Money?
A company’s cash runway is calculated by dividing its cash hoard by its cash burn. As at March 2026, PRISM BioLabLTD had cash of JP¥2.5b and no debt. Looking at the last year, the company burnt through JP¥1.3b. That means it had a cash runway of around 22 months as of March 2026. While that cash runway isn’t too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.
View our latest analysis for PRISM BioLabLTD
How Well Is PRISM BioLabLTD Growing?
At first glance it’s a bit worrying to see that PRISM BioLabLTD actually boosted its cash burn by 19%, year on year. Having said that, it’s revenue is up a very solid 74% in the last year, so there’s plenty of reason to believe in the growth story. The company needs to keep up that growth, if it is to really please shareholders. It seems to be growing nicely. Of course, we’ve only taken a quick look at the stock’s growth metrics, here. You can take a look at how PRISM BioLabLTD is growing revenue over time by checking this visualization of past revenue growth.
How Hard Would It Be For PRISM BioLabLTD To Raise More Cash For Growth?
Even though it seems like PRISM BioLabLTD is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company’s cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year’s operations.
PRISM BioLabLTD’s cash burn of JP¥1.3b is about 23% of its JP¥5.8b market capitalisation. That’s not insignificant, and if the company had to sell enough shares to fund another year’s growth at the current share price, you’d likely witness fairly costly dilution.
Is PRISM BioLabLTD’s Cash Burn A Worry?
Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought PRISM BioLabLTD’s revenue growth was relatively promising. Cash burning companies are always on the riskier side of things, but after considering all of the factors discussed in this short piece, we’re not too worried about its rate of cash burn. On another note, PRISM BioLabLTD has 4 warning signs (and 1 which doesn’t sit too well with us) we think you should know about.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
